Muromonab

Prior to Initiation of Therapy

• Should be administered under supervision of Experienced Personnel in Equipped Facility (for cardiopulmonary resuscitation)
• Anaphylactic and anaphylactoid reactions may occur following administration of any dose or course.
• Cardiotoxicity, CNS & Systemic Reactions: potentially life-threatening reactions including pulmonary edema, shock, cardiovascular collapse, cardiac/respiratory arrest, seizures, coma, cerebral edema, cerebral herniation, blindness and paralysis.
• Cytokine Release Syndrome

MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA

• Fluid status carefully monitored at baseline and during therapy
• Pretreatment with methylprednisolone to minimized Cytokine Release Syndrome

Package Inserts

Muromonab

Additional Information

• PubMed - Muromonab